Horizon Therapeutics plc Announces First Patient Enrolled in

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 randomized placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcrip...

Related Keywords

Ireland , California , United States , San Diego , American , Erin Linnihan , Eimear Rigby , Geoff Curtis , Theresa Podrebarac , Kenneth Kalunian , Tina Ventura , Nasdaq , Instagram , Facebook , Drug Administration , Corporate Affairs , Linkedin , Corporate Communications , Twitter , University Of California , Horizon Therapeutics , African American , Drug Evaluation , Surrogate Endpoints That Were , Drug Approval , Accessed July , Accessed June , Vice President , Chief Investor Relations Officer , Investor Relations , Chief Communications Officer ,